CARGO Therapeutics

CRGX

Market cap $216M

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra Biosciences. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, shareholders of CARGO will receive $4.379 in cash per share, plus one non-transferable continge.

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CARGO Therapeutics, Inc. (NasdaqGS: CRGX) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Concentra will acquire CARGO for $4.379 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of CA.

NEW YORK , July 25, 2025 /PRNewswire/ -- Class Action Attorney Juan Monteverde  with Monteverde & Associates PC  (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating CARGO Therapeutics, Inc. (NASDAQ: CRGX) related to its sale to Concentra Biosciences, LLC for $4.379 in cash per CARGO share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of the net proceeds from the sale, license, or other disposition of either (a) CRG-022, a CDRR CAR T-cell therapy, or (b) CRG-023, a CD19/CD20/CD22 tri-specific CAR T therapy, or (c) the Allogeneic Platform, that occurs within 2 years following the closing.

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating CARGO Therapeutics, Inc. (NASDAQ: CRGX ) related to its sale to Concentra Biosciences, LLC for $4.379 in cash per CARGO share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of the net proceeds from the sale, license, or other disposition of either (a) CRG-022, a CDRR CAR T-cell therapy, or (b) CRG-023, a CD19/CD20/CD22 tri-specific CAR T therapy, or (c) the Allogeneic Platform, that occurs within 2 years following the closing. Is it a fair deal?

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:

NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CARGO Therapeutics, Inc. (NasdaqGS: CRGX) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Concentra will acquire CARGO for $4.379 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash.

MILWAUKEE , July 8, 2025 /PRNewswire/ -- The Ademi Firm is investigating CARGO (NASDAQ: CRGX) for possible breaches of fiduciary duty and other violations of law in its transaction with Concentra Biosciences. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995.

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CARGO Therapeutics, Inc. (NASDAQ: CRGX) to Concentra Biosciences, LLC is fair to CARGO shareholders. Under the terms of the proposed transaction, Concentra will acquire CARGO for $4.379 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of any net pro.

SAN CARLOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (“CARGO” or the “Company”) (NASDAQ: CRGX), a biotechnology company that has focused on developing CAR T-cell therapies, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC (“Concentra”), whereby Concentra will acquire CARGO for $4.379 in cash per share of CARGO common stock, par value $0.001 per share (“CARGO Common Stock”), plus one non-transferable contingent value right (“CVR”), which represents the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of any net proceeds received within two years following closing from any disposition of certain of CARGO's product candidates that occurs within two years following closing, each pursuant to a contingent value rights agreement (the “CVR Agreement”).

- Development of CRG-023 and allogeneic platform suspended; further reduction in force (RIF) of approximately 90% to preserve cash and maximize shareholder value - - CARGO had cash, cash equivalents and marketable securities of $368.1 million as of December 31, 2024 - - Anup Radhakrishnan appointed as interim CEO to pursue reverse merger or other business combination - SAN CARLOS, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (Nasdaq: CRGX) today provided an update regarding its ongoing evaluation of strategic options following the discontinuation of FIRCE-1, a Phase 2 study of firicabtagene autoleucel (firi-cel).